Movement disorders induced by gamma-aminobutyric agonist and antagonist injections into the internal globus pallidus and substantia nigra pars reticulata of the monkey

Brain Research

Volumn 780, Issue 1, 1998, Pages 102-107

  Burbaud, P ^a   Bonnet, B ^a   Guehl, D ^a   Lagueny, A ^b   Bioulac, B ^a  

^a CNRS   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Bicuculline; Globus pallidus internalis; Intracerebral injections; Monkey; Muscimol; Substantia nigra pars reticulata

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; BICUCULLINE; MUSCIMOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; BODY MOVEMENT; CHOREA; CONTROLLED STUDY; DYSTONIA; GLOBUS PALLIDUS; HYPOKINESIA; LOCOMOTION; MOTOR CONTROL; MOTOR DYSFUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ANIMALS; BICUCULLINE; GABA AGONISTS; GABA ANTAGONISTS; GLOBUS PALLIDUS; INJECTIONS; MACACA FASCICULARIS; MOVEMENT DISORDERS; MUSCIMOL; SUBSTANTIA NIGRA;

EID: 0032484490     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)01158-X     Document Type: Article

References (33)

1. Albin G.E., Young A.B., Penney J.P. The functional anatomy of basal ganglia disorders. TINS. 12:1989;366-375.
2. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. TINS. 13:1990;266-271.
3. Benazzouz A., Gross Ch., Feger J., Boraud Th., Bioulac B. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur. J. Neurosc. 5:1993;382-389.
4. Bhatia K.P., Marsden C.D. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain. 117:1994;859-876.
5. Chan J., Brin M.F., Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov. Disord. 6:1991;119-126.
6. Chesselet M.A., Delfs J.M. Basal ganglia and movement disorders: an update. TINS. 19(10):1996;417-422.
7. Chevalier G., Deniau J.M. Disinhibition as a basic process in the expression of striatal functions. TINS. 13:1990;277-280.
8. Crossman A.R., Mitchell I.J., Sambrook M.A., Jackson A. Chorea and myoclonus in the monkey induced by gamma-amino-butyric acid antagonism in the lentiform complex. Brain. 111:1988;1211-1233.
9. A receptor subunit. Nature. 385:1997;820-823.
10. DeLong M.H. Primate models of movement disorders of basal ganglia origin. TINS. 13(7):1990;281-282.
11. K.I. Fujimoto, H. Yamada, E. Nakamura, S. Nakamura, S. Muramatsu, M. Yoshida, Potential changes within the basal ganglia during putamen-induced dystonia and caudate-induced locomotor hyperactivity in the freely moving cat, in: G. Percheron, J.S. McKenzie, J. Féger (Eds.), The Basal Ganglia IV, Plenum Press, New York, 1994, pp. 327-336.
12. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsm F.J., Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
13. W. Graham, R.G. Robertson, T.Z. Aziz, D. Peggs, I.J. Mitchell, M.A. Sambrook, A.R. Crossman, The role of the internal segment of the globus pallidus in mediating dyskinesias, in: G. Percheron, J.S. McKenzie, J. Féger (Eds.), The Basal Ganglia IV, Plenum Press, New York, 1994, pp. 349-354.
14. Hallett M. The physiology of basal ganglia disorders: an overview. Can. J. Neurol. Sci. 20:1993;177-183.
15. Hassani O.K., Mouroux M., Feger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion is independent of disinhibition via the globus pallidus. Neuroscience. 72(1):1996;105-115.
16. Kato M., Kimura M. Effects of reversible blockade of basal ganglia on a voluntary arm movement. J. Neurophysiol. 68:1992;1516-1534.
17. Kurlan R., Kim M.H., Gash D.M. Oral levodopa dose-response study in MPTP-induced hemiparkinson monkeys: assessement with a new rating scale for monkey parkinsonism. Mov. Disord. 6:1992;111.
18. Limousin P., Pollak P., Benazzouz A., Hoffman D., Broussolle E., Perret J.E., Benabid A.L. Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Mov. Disord. 10(5):1995;672-674.
19. J.S. Mc Kenzie, A.D. Shafton, C.A. Stewart, Motor responses to GABAergic interference in the rat entopedoncular nucleus in relation to rotation behaviour, in: M.B. Carpenter, A. Jaramayan, (Eds.), The basal ganglia, II. Struture and function - current concepts, Plenum Press, New York, 1992, pp. 327-335.
20. Mink J.W., Thach W.T. Basal ganglia in motor control. III Pallidal ablation: normal reaction time, muscle cocontraction and slow movement. J. Neurophysiol. 65(2):1991;330-351.
21. Mitchell I.J., Luquin R., Boyce S., Clarke C.E., Robertson R.G., Sambrook M.A., Crossman A.R. Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. Mov. Disord. 5(1):1990;49-54.
22. Mitchell I.J., Sambrook M.A. Crossman. Subcortical changes in the regional uptake of {3H}-2-Deoxyglucose in the brain of the monkey during experimental choreiform dyskinesia elicited by injection of a gamma-amino-butyric acid antagonist into the subthalamic nucleus. Brain. 108:1985;405-422.
23. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Rev. 20:1995;91-127.
24. Parent A., Côté P.Y., Lavoie B. Chemical anatomy of primate basal ganglia. Prog. Neurobiol. 46:1995;131-197.
25. Poewe W.H., Lees A.J., Stern G.M. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann. Neurol. 23:1988;73-78.
26. Richter A., Löscher W. The atypical neuroleptic, clozapine, exerts antidystonic activity in a mutant hamster model. Comparison with haloperidol. Eur. J. Pharmacol. 242:1993;309-312.
27. Robertson R.G., Crossman A.R.et al. Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus. Brain Res. 476:1989;317-322.
28. Siegfried J., Lippitz B. Bilateral chronic electrostimulation of ventroposterolateral pallidum: A New therapeutic approach for alleviating all parkinsonian symptoms. Neurosurgery. 35(6):1994;1126-1130.
29. Szabo J., Cowan W.M. A stereotaxic atlas of the Brain of the Cynomolgus monkey (Macaca fascicularis). J. Comp. Neurol. 222:1984;265-300.
30. Starr M.S. Glutamate/Dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse. 19:1995;264-293.
31. A receptor-mediated inhibition of rat substantia nigra dopaminergic neurons by pars reticulata projections neurons. J. Neurosci. 15(4):1995;3092-3103.
32. Trugman J.M., Leadbetter R., Zalis M.E., Burdorf R.O., Wooten G.F. Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis. Mov. Disord. 9(4):1994;441-446.
33. Turski L., Klockgether T., Turski W., Schwarz M., Sontag K.H. Blockade of excitatory neurotransmission in the globus pallidus induces rigidity and akinesia in the rat: implications for excitatory neurotransmission in pathogenesis of Parkinson's disease. Brain Res. 512:1990;125-131.